Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate

International Clinical Psychopharmacology

Volumn 12, Issue 5, 1997, Pages 255-261

  Regenthal, R ^a   Kunstler U ^a   Junhold, U ^a   Preiss, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antipsychotic efficacy; D2 dopamine receptors; Haloperidol decanoate; Low dose treatment; Schizophrenia; Serum concentrations; Single photon emission computed tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL DECANOATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031437470     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199709000-00002     Document Type: Article

References (24)

1. Avent KM, Usuki E, Eyles DW, Keeve R, Van der Schyf CJ, Castagnoli N Jr and Pond SM (1996) Haloperidol and its tetrahydropyridine derivative (hptp) are metabolized to potentially neurotoxic pyridinium species in the baboon. Life Sciences, 59, 1473-1482.
2. Baldessarini RJ, Cohen BM and Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 79-91.
3. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C and Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology, 99, 463-472.
4. Benkert O and Hippius H (1996) Psychiatric Pharmacotherapy, 6th edn, pp. 229-231. Springer, Berlin, Heidelberg, New York.
5. Burnett PL, Gallety CA, Moyle RJ and Clark CR (1993) Low-dose medication in schizophrenia. Schizophrenia Bulletin, 53, 426-433.
6. Ereshfsky L (1995) Ein pharmakodynamisches und pathophysiologisches modell der medikamentösen antipsychotischen therapie der schizophrenie [in German]. In: Schizophrenie. Dopaminrezeptoren und Neuroleptika, (Ed. J Gerlach), pp. 148-187. Springer, Berlin, Heidelberg, New York.
7. Eyles DW, McGrath JJ and Pond SM (1996) Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology, 125, 214-219.
8. Farde L, Hall H, Ehrin E and Sedvall G (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science, 231, 258-261.
9. Janssen PAJ and Awouters FHL (1995) Antipsychotic agents. In: Principles of Pharmacology (Eds PL Munson, RA Mueller and GR Breese), pp. 259-308. Chapman & Hall, New York, Albany, Bonn.
10. Kane JM (1989) The current status of neuroleptic therapy. Journal of Clinical Psychiatry, 50, 322-328.
11. Kay SR, Fiszbein A and Opler LA (1987) Positive and negative syndrome scale for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
12. Langen KJ, Herzog H (1995) SPECT versus PET [in German]. In: Single-Photon-Emissions-Computertomagraphie SPECT des Gehirns (Ed. HJ Wieler), pp. 237-249. Springer, Berlin, Heidelberg, New York.
13. McEvoy JP, Stiller RL and Farr R (1986) Plasma haloperidol levels drawn at neuroleptic threshold dose: a pilot study. Journal of Clinical Psychopharmacology, 6, 133-137.
14. Nyberg S, Farde L, Halldin C, Dahl ML and Bertilsson L (1995a) D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. American Journal of Psychiatry, 152, 173-178.
15. 2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. International Clinical Psychopharmacology, 10, (suppl 3), 81-85.
16. Odou P, Vaiva G, Luyckx M, Brunet C, Dine T, Gressier B, Cazin M and Cazin JC (1996) Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol. European Journal of Clinical Pharmacology, 50, 357-363.
17. Palao DJ, Arauxo A, Brunet M, Bernado M, Haro J, Ferrer J and Gonzalez-Monclus E (1994) Haloperidol: therapeutic window in schizophrenia. Journal of Clinical Psychopharmacology, 14, 303-310.
18. Simpson GM and Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212 (suppl), 11-19.
19. 18F] N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biological Psychiatry, 23, 653-663.
20. Van Putten T, Marder SR, Wirshing WC, Aravagiri M and Chabert N (1991) Neuroleptic plasma levels. Schizophrenia Bulletin, 17, 197-216.
21. Van Putten T, Marder SR, Mintz J and Poland RE (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship. American Journal of Psychiatry, 149, 500-505.
22. Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, Gastanaga P, Krakowski M, Chou JCY, Crowner M and Doulyon R (1992) Haloperidol blood levels and clinical effects. Archives of General Psychiatry, 49, 354-361.
23. Wiesel FA (1994) Neuroleptic treatment of patients with schizophrenia. Mechanism of action and clinical significance. British Journal of Psychiatry, 23, 65-70.
24. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf JAP, Smith M, Fowler JS, Cooper TB (1989) Dopamine receptor occupancy and haloperidol levels [letter]. Archives of General Psychiatry, 46, 482-484.